This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 1.
Correlation between baseline (D0) antibody levels and 6 months after vaccination (D3). Blue rings present individual results; red line – 95% confidence interval (CI)
Figure 2.
Initial antibody level for groups A (COVID-19 convalescents with increase of antibody level after 2nd dose) and C (COVID-19 convalescent, who had lower antibody level after 2nd dose compared to the results after 1st dose) and BMI level. Blue rings present individual results; red line – 95% confidence interval (CI)
Figure 3.
Antibody levels 6 months after vaccination (D3) for group A (COVID-19 convalescents with increase of antibody level after 2nd dose), B (naïve patients) and C (COVID-19 convalescent, who had lower antibody level after 2nd dose compared to the results after 1st dose). Whiskers drawn from minimum (min) to maximum (max).
Figure 4.
Delta (difference) between antibody levels 1 month after vaccination (D2) and 6 months after vaccination (D3)
Minimal (min), maximal (max), median (Me), IQR (Interquartile range), SD (standard deviation) and mean results [IU/ml] on following stages of the study. A (COVID-19 convalescents with increase of antibody level after 2nd dose) – 27 patients, B (naïve patients) - 30, C (COVID-19 convalescent, who had lower antibody level after 2nd dose compared to the results after 1st dose). - 30; 87 participants in total. P-value was find using Kruskal-Wallis test
group
Mean [IU/mL]
SD [IU/mL]
Min-max [IU/mL]
Me [IQR] [IU/mL]
P
D0
A
162.4
182.8
0.0–896.0
92.8 [44.2–227.7]
0.000
C
222.0
289.5
0.0–1344.0
128.1 [83.2–268.8]
B
0.000
0.000
0.0–0.0
0.000 [0–0]
total
127.0
218.0
0.0–1344.0
57.6 [0.0–144.5]
D1
A
5959.5
2415.7
1830.4–11392.0
5587.2 [4480.0–7680.0]
0.000
C
7638.5
5390.0
1968.0–21800.0
5472.0 [4000.0–8256.0]
B
856.0
875.1
185.6–3088.0
536.0 [320.0–889.6]
total
4778.6
4525.2
185.6–21800.0
4000.0 [777.9–6075.0]
D2
A
7664.4
2616.5
3360.0–14360.0
7520.0 [4992.0–9280.0]
0.000
C
5547.2
3845.9
1129.0–19840.0
4608.0 [3120.0–7456.0]
B
4451.9
1569.1
1664.0–7680.0
4032.0 [3360.0–5440.0]
total
5826.6
3103.9
1129.0–19840.0
4832.0 [3456.0–7536.0]
D3
A
2417.1
1480.2
344.0–7316.0
2336.0 [1453.0–3096.0]
0.000
C
2146.4
2453.0
236.0–12099.0
1462.5 [819.0–2177.0]
B
965.4
485.8
340.0–2650.0
819.0 [609.0–1216.0]
total
1823.2
1781.8
236.0–12099.0
1301.0 [806.0–2336.0]
Correlation between baseline (D0) antibody levels and further sampling (D1 - after 1st dose - up to 7 days before the second dose, D2 – 1 month after vaccination, D3 – 6 months after vaccination)
Antibody levels
Spearman rank correlation
N
R Spearman
p
D0 & D1
87
0.73
0.000
D0 & D2
87
0.34
0.001
D0 & D3
87
0.45
0.000
Delta (difference) between antibody levels 1 month after vaccination (D2) and 6 months after vaccination (D3); minimal (min), maximal (max), median (Me), IQR, SD (standard deviation), N – number of subjects, total – summary number of participants. P-value was find using Kruskal-Wallis test